Mixed HTA Results As Scotland Says No To Yescarta But Yes To Kymriah
The Scottish Medicines Consortium has recommended one CAR-T therapy, Novartis’ Kymriah, for use on Scotland’s National Health Service but rejected another, Gilead’s Yescarta, claiming the company has failed to prove it would be cost-effective.
You may also be interested in...
The Scottish health technology appraisal body, the SMC, has okayed Gilead’s CAR-T therapy Yescarta for use on the Scottish National Health Service.
Novartis has managed to temporarily overcome payer reservations about the real-world value of Kymriah by engaging early with payers and heath technology assessment bodies and by developing tailored outcomes-based deals for key European markets. Approaching each payer with a responsible attitude has helped too.
Payment for outcomes has played an important role in enabling Gilead to secure reimbursement for Yescarta in some EU markets. It is likely to be the key focus for the company as it works to expand patient access to the potentially transformative CAR-T therapy across Europe.